Effect of Immunosuppressive or Immunomodulatory Agents on Severe COVID-19 Outcomes: A Population-Based Cohort Study.

Shelby MarozoffJeremiah TanNa LuAyesha KirmaniJonathan M LoreeHui Xie Diane LacailleJacek A KopecJohn M EsdaileBonnie CorradettiPeter MaloneCheryl L KoehnPhilippa MennellAlison M HoensJuan Antonio Aviña-Zubieta

Published in: ACR open rheumatology (2023)

Current use of MMF and glucocorticoids were associated with an increased risk of severe COVID-19 outcomes compared with nonuse. These results emphasize the variety of circumstances of patients taking IIAs.

Keyphrases

coronavirus disease
sars cov
end stage renal disease
ejection fraction
newly diagnosed
early onset
prognostic factors
peritoneal dialysis
patient reported outcomes
drug induced
insulin resistance